MYOMO, INC. (MYO) is a leading medical robotics company based in the United States. The company is primarily known for its innovative wearable robotics and orthotics, designed to enable users to overcome mobility constraints associated with various neurological disorders and injuries.
Established in 2004, MYOMO, INC. operates with the vision to improve the lives of individuals with neuromuscular disorders, facilitating their independence by offering innovative robotics solutions. The name 'MYOMO' is actually an acronym for "My Own Motion," aptly reflecting the firm's mission to aid people in reclaiming their mobility and effectively carrying out routine activities.
MYOMO's flagship product is the MyoPro©, a robotic arm brace that augments muscle strength in users affected by muscle weakness or paralysis due to stroke, traumatic injury, or neuro-muscular disease such as Multiple Sclerosis or ALS. This life-changing technology, licensed from the Massachusetts Institute of Technology (MIT), is the only one of its kind in the marketplace.
Critically, the MyoPro© is not just a mobility aid – it is a powered brace that can actually enable the user to regain the ability to conduct tasks that they may not have been able to do since their injury or diagnosis. The device is customizable to each individual user and is designed to interpret faint nerve signals and enable controlled, functional movement.
MYOMO continues to lead in its field by combining intensive customer feedback, cutting-edge engineering, and a human-first approach. This method has enabled MYO to secure coverage for its MyoPro© line of products within numerous insurance providers, including Medicare and top private insurance carriers, making these critical mobility solutions more accessible to those in need.
MYOMO, INC. is more than just a company that sells products. It has goals that are deeply rooted in improving people's lives by aiding their physical mobility. Its commitment to excellence and innovative solutions has placed the company at the forefront of medical robotic technology, helping countless individuals reclaim their independence and live life on their terms. The organization aims to continue its investment in research and development to further enhance its products, solidifying its commitment to its users and the broader medical and scientific community.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Myomo Inc. reported a 21% year-over-year revenue increase to $11.7 million in Q2 2026, driven by a strategic shift to recurring patient referrals, which now constitute 53% of total revenue. The company demonstrated strong operational leverage, with operating expenses growing only 1% and adjusted EBITDA improving significantly. Myomo also raised its full-year revenue guidance to $45-47 million, indicating continued business momentum and progress in product development, including a new hand-only device prototype for the German market.
This article identifies three promising penny stocks: Myomo (MYO), Xtant Medical Holdings (XTNT), and CS Disco (LAW). Myomo shows revenue growth and near-term financial stability despite unprofitability. Xtant Medical Holdings is expanding market reach through partnerships but faces declining revenue and net losses, while CS Disco, though unprofitable, has strong cash reserves and no debt, focusing on AI-powered legal solutions.
Myomo (NYSEAMERICAN:MYO) insider Harry Kovelman sold 17,250 shares of the company's stock for $29,842.50, reducing his ownership by 14% to 105,983 shares. Despite the insider selling, Myomo shares are trading near their 52-week high, and the company recently surpassed analyst expectations for quarterly revenue and EPS. Analysts maintain a "Buy" rating with an average price target of $10.00, and institutional investors hold approximately 44.99% of the stock.
Rosalind Advisors, Inc. significantly increased its stake in Myomo Inc (MYO) by purchasing 3,553,872 shares, bringing their total holdings to 7,401,144 shares. This investment now constitutes 3.07% of Rosalind Advisors' portfolio, and the stock has appreciated 61.54% since the purchase. Despite Myomo Inc. showing some growth in EBITDA and earnings, it currently faces significant financial challenges, including unprofitability, weak financial strength, and a "Possible Value Trap" designation from GF Valuation.